Allergy Therapeutics plc (LON:AGY – Get Free Report)’s share price dropped 11.3% during mid-day trading on Wednesday . The company traded as low as GBX 5.40 and last traded at GBX 5.50. 370,638 shares changed hands during trading, an increase of 39% from the average daily volume of 266,926 shares. The stock had previously closed at GBX 6.20.
Allergy Therapeutics Trading Down 11.3%
The company has a debt-to-equity ratio of 629.58, a quick ratio of 1.48 and a current ratio of 1.13. The firm has a fifty day moving average price of GBX 7.91 and a 200 day moving average price of GBX 9.86. The company has a market cap of £348.29 million, a price-to-earnings ratio of -5.67, a P/E/G ratio of -30.70 and a beta of 0.87.
Allergy Therapeutics Company Profile
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
See Also
- Five stocks we like better than Allergy Therapeutics
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
- Boxabl Disrupts Housing With A Tiny Float IPO
- Robotaxi Mode Engaged: Tesla Starts Monetizing Its Florida Fleet
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
